常山药业(300255) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥436,193,853.25, representing a year-on-year growth of 19.08%[7] - Net profit attributable to shareholders was ¥54,886,990.11, up 11.41% from the same period last year[7] - The net profit after deducting non-recurring gains and losses was ¥54,533,237.82, reflecting an increase of 11.16% year-on-year[7] - The basic earnings per share for the reporting period was ¥0.06, a rise of 20.00% compared to the previous year[7] - The weighted average return on equity was 2.24%, an increase of 0.12% from the previous year[7] - The net profit for the year-to-date was ¥160,979,927.67, which is a 21.18% increase compared to the same period last year[7] - The total operating profit for the year-to-date period reached ¥186,320,694.72, a rise of 18.3% from ¥157,511,971.82[43] - The net profit attributable to the parent company for the year-to-date period was ¥160,979,927.67, compared to ¥132,838,657.04 in the previous year, marking a growth of 21.1%[44] - The net profit for the third quarter of 2018 was CNY 161,169,675.84, an increase of 22.4% compared to CNY 131,708,968.38 in the same period last year[48] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,672,437,842.11, an increase of 4.03% compared to the end of the previous year[7] - The company's total assets reached CNY 3,711,882,727.14, an increase from CNY 3,467,406,055.61 at the beginning of the year, marking a growth of 7.0%[32] - The total liabilities increased to CNY 1,159,050,565.85 from CNY 1,057,044,232.60, indicating a rise of 9.7%[32] - The total equity attributable to shareholders rose to CNY 2,552,832,161.29 from CNY 2,410,361,823.01, an increase of 5.9%[32] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥37,645,343.75, a significant increase of 129.57%[7] - The cash flow from operating activities generated a net amount of CNY 37,645,343.75, a significant improvement from a net outflow of CNY -127,322,370.22 in the previous year[52] - Cash inflow from sales of goods and services reached CNY 1,440,067,402.98, compared to CNY 896,541,109.53 in the prior period, indicating a growth of 60.8%[51] - The total cash outflow from operating activities was CNY 1,409,921,853.73, which is an increase from CNY 1,040,339,551.29 year-over-year[52] - The company reported a cash and cash equivalents balance of CNY 421,877,962.78 at the end of the period, down from CNY 541,121,017.71 at the beginning of the period[53] - The company incurred a total of CNY 159,430,574.59 in cash outflows for investment activities, compared to CNY 108,752,727.22 in the previous year[52] - The cash flow from financing activities resulted in a net inflow of CNY 1,639,175.91, a decrease from CNY 109,293,764.77 in the same period last year[53] Expenses - Operating revenue increased by 30.71% year-on-year, primarily due to increased sales volume of heparin sodium raw materials and water injection preparations[15] - Research and development expenses rose by 37.53% year-on-year, reflecting the company's increased investment in R&D[15] - Financial expenses increased by 33.54% year-on-year, mainly due to increased borrowings and interest expenses[15] - Sales expenses increased by 43.87% year-on-year, primarily due to higher marketing expenses[15] - Research and development expenses were CNY 31,137,192.57, up from CNY 22,307,856.88, reflecting an increase of 39.7% year-over-year[35] - The financial expenses for the year-to-date period were ¥24,943,123.16, an increase of 33.5% from ¥18,678,040.84[43] Shareholder Information - The company reported a total of 35,490 common shareholders at the end of the reporting period[11] - The largest shareholder, Gao Shuhua, holds 35.69% of the shares, with 255,296,046 shares pledged[11] Production and Operations - The company has not experienced any significant changes in production and operation, and all work including R&D, production, and sales is proceeding in an orderly manner[17]